Alk-Abello A/S

ALK B

Equity

ISIN DK0061802139 / Valor 117689788

Nasdaq Copenhagen Equities (2024-09-18)

DKK 178.00%

Alk-Abello A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

ALK-Abelló A/S, commonly referred to as ALK, is a Denmark-based pharmaceutical company specializing in the development and production of treatments for allergies. Since its inception in 1923 by pharmacist Peter Barfod and physician Kaj Baagøe, ALK has been at the forefront of allergy treatment innovation. The company has a rich history of pioneering advancements in the field, including the development of the first pharmaceutically manufactured allergen extract and the introduction of standardized methods for large-scale manufacturing of allergen extracts. In recent years, ALK has focused on expanding its portfolio of sublingual allergy immunotherapy (SLIT) tablets, aiming to cover five of the most common respiratory allergies. These include house dust mite, grass, trees from the birch family, ragweed, and Japanese cedar allergies, with products already available in many markets. Additionally, in 2018, ALK launched klarify.me, a sister brand offering a range of drug-free products and services to help individuals manage their allergies. The company's strategic investments and innovations underscore its commitment to transforming into a broader-based allergy company, reaching a wider audience and capturing a larger share of the global allergy market.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first quarter of 2024, Alk-Abello A/S reported a significant increase in revenue, with a growth rate of 10-13% in local currencies. This growth was primarily driven by broad-based expansion across various sales regions and product groups, particularly in European tablet sales.

EBIT Margin Improvement

Alk-Abello A/S's EBIT margin for Q1 2024 showed a notable improvement, rising to 17-19% from 14% in the previous year. This enhancement was attributed to increased sales volumes, operational efficiencies, and reduced R&D costs.

Tablet Sales Performance

Tablet sales for Alk-Abello A/S in Q1 2024 experienced double-digit growth. This surge was fueled by the expansion of patient and prescriber bases, market share gains, and a shift towards evidence-based medicine in key markets, particularly in Europe.

Cost Management

During Q1 2024, Alk-Abello A/S managed to keep its capacity costs in check, with the cost-to-revenue ratio showing further improvement. This was achieved through enhanced efficiencies, reduced R&D expenditure, and strategic optimization measures.

Outlook for 2024

Alk-Abello A/S has upgraded its full-year financial outlook for 2024, expecting revenue to grow by 10-13% organically in local currencies. The company anticipates continued growth in tablet sales, particularly in Europe, and an improved EBIT margin of 17-19% for the year.

Summarized from source with an LLMView Source

Key figures

118%1Y

25.5%3Y

164%5Y

Performance

37.1%1Y

40.6%3Y

38.8%5Y

Volatility